Effects of co-administration of bupropion and nicotine or D-amphetamine on the elevated plus maze test in mice

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 4, 2009, Pages 493-502

  Biala, Grazyna ^a   Kruk, Marta ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Anxiety; Bupropion; Elevated plus maze test; Psychostimulant

Indexed keywords

AMFEBUTAMONE; DEXAMPHETAMINE; NICOTINE; ANTIDEPRESSANT AGENT;

ACUTE DRUG ADMINISTRATION; ADDICTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; CROSS TOLERANCE; DRUG EFFECT; DRUG MECHANISM; MALE; MAZE TEST; MOUSE; NONHUMAN; TRANQUILIZING ACTIVITY; ANIMAL; DOSE RESPONSE; DRUG INTERACTION; DRUG TOLERANCE; MOTOR ACTIVITY; NEWBORN;

ANIMALS; ANIMALS, NEWBORN; ANTIDEPRESSIVE AGENTS; ANXIETY; BUPROPION; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOLERANCE; MALE; MAZE LEARNING; MICE; MOTOR ACTIVITY; NICOTINE;

EID: 85047684826     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.04.0012     Document Type: Article

References (43)

1. Slemmer JE et al. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321-327.
2. Cryan JF et al. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 2003; 168: 347-358.
3. Malin DH et al. Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology 2006; 184: 494-503.
4. Li SX et al. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 2002; 42: 181-190.
5. Brandon TH et al. Expectancies for tobacco smoking. In: Kirsh I, ed. How Expectancies Shape Experience. Washington, DC: American Psychological Association, 1999: 263-299.
6. Jackson KJ et al. Differential role of nicotine acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther 2008; 325: 302-312.
7. Broni JD et al. Nicotine receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 1993; 238: 1-8.
8. Ouagazzal AM et al. Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology 1999; 144: 54-60.
9. Irvine EE et al. Development of tolerance to nicotine's anxiogenic effect in the social interaction test. Brain Res 2001; 894: 95-100.
10. Pellow S et al. Validation of open:closed arm entries in an elevated plus maze as a measure of anxiety in the rats. J Neurosci Methods 1985; 14: 149-167.
11. Lapin IP. Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. Pharmacol Biochem Behav 1993; 44: 241-243.
12. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987; 92: 180-185.
13. Dawson GR et al. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology 1995; 118: 316-323.
14. Kliethermes CL et al. Validation of a modified mirrored chamber sensitive to anxiolytics and anxiogenics in mice. Psychopharmacology 2003; 169: 190-197.
15. Salas R et al. Altered anxiety-related responses in mutant mice lacking the β4 subunit of the nicotinic receptor. J Neurosci 2003; 23: 6255-6263.
16. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997; 20: 92-98.
17. Bergink V et al. Glutamate and anxiety. Eur Neuropsychopharmacol 2004; 14: 175-183.
18. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987; 94: 469-492.
19. Lin HQ et al. The anxiogenic-like and anxiolytic-like effects of MDMA on mice in the elevated plus-maze: a comparison with amphetamine. Pharmacol Biochem Behav 1999; 62: 403-408.
20. Carrasco MC et al. Effects of co-administation of bupropion and nicotine agonists on the elevated plus-maze test in mice. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 455-462.
21. Biala G, Kruk M. Calcium channel antagonists suppress crosstolerance to the anxiogenic effects of D-amphetamine and nicotine in the mouse elevated plus maze. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 54-61.
22. Cancela LM et al. A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study. Brain Res 2001; 909: 179-186.
23. Williamson S et al. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 1997; 44: 87-94.
24. Damaj MI. Calcium-acting drugs modulate expression and development of chronic tolerance to nicotine-induced antinociception in mice. J Pharmacol Exp Ther 2005; 315: 959-964.
25. Birrell CE, Balfour DJK. The influence of nicotine pretreatment on mesoaccumbens dopamine overflow and locomotor responses to D-amphetamine. Psychopharmacology 1998; 140: 142-149.
26. Schoffelmeer ANM et al. Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation. J Neurosci 2002; 22: 3269-3276.
27. Vezina P et al. Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1625-1638.
28. Desai R, Terry P. Evidence of cross-tolerance between behavioural effects of nicotine and cocaine in mice. Psychopharmacology 2003; 166: 111-119.
29. Collins SL, Izenwasser S. Chronic nicotine differentially alters cocaine-induced locomotor activity in adolescent vs. adult male and female rats. Neuropharmacology 2004; 46: 349-362.
30. Celik E et al. Caffeine and amphetamine produce cross-sensitization to nicotine-induced locomotor activity in mice. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 50-55.
31. Dwoskin LP et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drugs Rev 2006; 12: 178-207.
32. Glick SD et al. Modulation of nicotine self-administration in rats by combination therapy with agents blocking alpha 3 beta 4 nicotinic receptors. Eur J Pharmacol 2002; 448: 185-191.
33. Rauhut AS et al. Effects of bupropion on nicotine self-administration in rats. Psychopharmacology 2004; 169: 1-9.
34. Shoaib M et al. Investigating the actions of bupropion on dependence-related effects of nicotine in rats. Psychopharmacology 2003; 165: 405-412.
35. File SE et al. Neurobiological mechanisms by which nicotine mediates different types of anxiety. Eur J Pharmacol 2000; 393: 231-236.
36. Pezze MA, Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol 2004; 74: 301-320.
37. Sidhpura N et al. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem Pharmacol 2007; 74: 1292-1298.
38. 3]norepinephrine. J Pharmacol Exp Ther 2002; 302: 1113-1122.
39. Soroko FE et al. Bupropion hydrochloride (da-t-butylamino-3- chloropropiophenone HCl), a novel antidepressant agent. J Pharm Pharmacol 1977; 29: 767-770.
40. Nomikos GG et al. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 1989; 2: 273-279.
41. Bredeloux P et al. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br J Pharmacol 2007; 150: 711-719.
42. Elkashef AM et al. Bupropion for the treatment of metamphetamine dependence. Neuropsychopharmacology 2008; 33: 1162-1170.
43. Jorenby DE et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.